Press Releases Guardant Health, Inc.

Equities

GH

US40131M1099

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
18 ^USD	-1.04%		+3.81%	-33.46%

04-29	Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating	MT
04-22	Sector Update: Health Care Stocks Increase Late Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Advisory Panel Review of Guardant Health's Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23	04-23	AQ
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23	04-22	BU
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024	04-18	BU
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	04-03	BU
Guardant Health - Royal Marsden And Guardant Health Partnership Provides State-of-the-art Blood Test To Benefit Lung Cancer Patients In Expanded NHS Study	03-25	AQ
Blood test shows 83% accuracy for detecting colorectal cancer in trial	03-13	AQ
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine	03-13	BU
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03-06	BU
Guardant Health, Inc. - New Survey, Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap	03-04	AQ
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap	03-01	BU
Guardant Health: Q4 Earnings Snapshot	02-22	AQ
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook	02-22	BU
Guardant Health to Participate in Upcoming Investor Conferences	02-15	BU
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024	02-01	BU
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence	01-17	BU
Guardant Health Announces Preliminary Fourth Quarterand Full Year 2023 Results	01-09	AQ
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results	01-08	BU
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer	01-02	BU
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford	12-21	BU
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	12-20	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Guardant Health, Inc.

Equities

GH

US40131M1099

Press Releases

Filters